"The U.S. Food and Drug Administration today approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).
CLL is a blood and bone ma"...
Mechanism Of Action
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.
In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
Maximum plasma concentrations (Cmax) of dasatinib are observed between 0.5 and 6 hours (Tmax) following oral administration. Dasatinib exhibits dose proportional increases in AUC and linear elimination characteristics over the dose range of 15 to 240 mg/day. The overall mean terminal half-life of dasatinib is 3 to 5 hours.
Data from a trial of 54 healthy subjects administered a single, 100-mg dose of dasatinib 30 minutes following consumption of a high-fat meal resulted in a 14% increase in the mean AUC of dasatinib. The observed food effects were not clinically relevant.
In patients, dasatinib has an apparent volume of distribution of 2505 L, suggesting that the drug is extensively distributed in the extravascular space. Binding of dasatinib and its active metabolite to human plasma proteins in vitro was approximately 96% and 93%, respectively, with no concentration dependence over the range of 100 to 500 ng/mL.
Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4. CYP3A4 was the primary enzyme responsible for the formation of the active metabolite. Flavincontaining monooxygenase 3 (FMO-3) and uridine diphosphate-glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites.
The exposure of the active metabolite, which is equipotent to dasatinib, represents approximately 5% of the dasatinib AUC. This indicates that the active metabolite of dasatinib is unlikely to play a major role in the observed pharmacology of the drug. Dasatinib also had several other inactive oxidative metabolites.
Dasatinib is a weak time-dependent inhibitor of CYP3A4. At clinically relevant concentrations, dasatinib does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 2E1. Dasatinib is not an inducer of human CYP enzymes.
Elimination is primarily via the feces. Following a single oral dose of [14C]-labeled dasatinib, approximately 4% and 85% of the administered radioactivity was recovered in the urine and feces, respectively, within 10 days. Unchanged dasatinib accounted for 0.1% and 19% of the administered dose in urine and feces, respectively, with the remainder of the dose being metabolites.
Effects of Age and Gender
Pharmacokinetic analyses of demographic data indicate that there are no clinically relevant effects of age and gender on the pharmacokinetics of dasatinib.
Dasatinib doses of 50 mg and 20 mg were evaluated in eight patients with moderate (Child-Pugh class B) and seven patients with severe (Child-Pugh class C) hepatic impairment, respectively. Matched controls with normal hepatic function (n=15) were also evaluated and received a dasatinib dose of 70 mg. Compared to subjects with normal liver function, patients with moderate hepatic impairment had decreases in dose-normalized Cmax and AUC by 47% and 8%, respectively. Patients with severe hepatic impairment had dose-normalized Cmax decreased by 43% and AUC decreased by 28% compared to the normal controls.
These differences in Cmax and AUC are not clinically relevant. Dose adjustment is not necessary in patients with hepatic impairment.
Newly Diagnosed Chronic Phase CML
An open-label, multicenter, international, randomized trial was conducted in adult patients with newly diagnosed chronic phase CML. A total of 519 patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily. Patients with a history of cardiac disease were included in this trial except those who had a myocardial infarction within 6 months, congestive heart failure within 3 months, significant arrhythmias, or QTc prolongation. The primary endpoint was the rate of confirmed complete cytogenetic response (CCyR) within 12 months. Confirmed CCyR was defined as a CCyR noted on two consecutive occasions (at least 28 days apart).
Median age was 46 years in the SPRYCEL group and 49 years in the imatinib groups, with 10% and 11% of patients ≥ 65 years of age, respectively. There were slightly more male than female patients in both groups (59% vs 41%). Fifty-three percent of all patients were Caucasian and 39% were Asian. At baseline, the distribution of Hasford Scores was similar in the SPRYCEL and imatinib treatment groups (low risk: 33% and 34%; intermediate risk: 48% and 47%; high risk: 19% and 19%, respectively). With a minimum of 12 months follow-up, 85% of patients randomized to SPRYCEL and 81% of patients randomized to imatinib were still on study.
With a minimum of 24 months follow-up, 77% of patients randomized to SPRYCEL and 75% of patients randomized to imatinib were still on study and with a minimum of 60 months follow-up, 61% and 62% of patients, respectively, were still on treatment at the time of study closure.
Efficacy results are summarized in Table 9.
Table 9: Efficacy Results in a Randomized Newly
Diagnosed Chronic Phase CML Trial
|Within 12 months (95% CI)||76.8% (71.2-81.8)||66.2% (60.1-71.9)|
|Major Molecular Reponseb|
|12 months (95% CI)||52.1% (45.9-58.3)||33.8% (28.1-39.9)|
|60 months (95% CI)||76.4% (70.8-81.5)||64.2% (58.1-70.1)|
|a Confirmed CCyR is defined as a CCyR noted on two
consecutive occasions at least 28 days apart.
bMajor molecular response (at any time) was defined as BCR-ABL ratios ≤ 0.1% by RQ-PCR in peripheral blood samples standardized on the International scale. These are cumulative rates representing minimum follow up for the time frame specified.
* Adjusted for Hasford Score and indicated statistical significance at a pre-defined nominal level of significance.
CI = confidence interval.
The confirmed CCyR within 24, 36, and 60 months for SPRYCEL versus imatinib arms were 80% versus 74%, 83% versus 77%, and 83% versus 79%, respectively. The MMR at 24 and 36 months for SPRYCEL versus imatinib arms were 65% versus 50% and 69% versus 56%, respectively.
After 60 months follow-up, median time to confirmed CCyR was 3.1 months in 215 SPRYCEL responders and 5.8 months in 204 imatinib responders. Median time to MMR after 60 months follow-up was 9.3 months in 198 SPRYCEL responders and 15.0 months in 167 imatinib responders.
At 60 months, 8 patients (3%) on the dasatinib arm progressed to either accelerated phase or blast crisis while 15 patients (6%) on the imatinib arm progressed to either accelerated phase or blast crisis.
The estimated 60-month survival rates for SPRYCEL-and imatinib-treated patients were 90.9% (CI: 86.6%–93.8%) and 89.6% (CI: 85.2%–92.8%), respectively. Based on data 5 years after the last patient was enrolled in the trial, 83% and 77% of patients were known to be alive in the dasatinib and imatinib treatment groups, respectively, 10% were known to have died in both treatment groups, and 7% and 13% had unknown survival status in the dasatinib and imatinib treatment groups, respectively.
At 60 months follow-up, in the SPRYCEL arm, the rate of MMR at any time in each risk group determined by Hasford score was 90% (low risk), 71% (intermediate risk) and 67% (high risk). In the imatinib arm, the rate of MMR at any time in each risk group determined by Hasford score was 69% (low risk), 65% (intermediate risk), 54% (high risk).
BCR-ABL sequencing was performed on blood samples from patients in the newly diagnosed trial who discontinued dasatinib or imatinib therapy. Among dasatinib-treated patients the mutations detected were T315I, F317I/L, and V299L.
Dasatinib does not appear to be active against the T315I mutation, based on in vitro data.
Imatinib Resistant Or Intolerant CML Or Ph+ ALL
The efficacy and safety of SPRYCEL were investigated in adult patients with CML or Ph+ ALL whose disease was resistant to or who were intolerant to imatinib: 1158 patients had chronic phase CML, 858 patients had accelerated phase, myeloid blast phase, or lymphoid blast phase CML, and 130 patients had Ph+ ALL. In a clinical trial in chronic phase CML, resistance to imatinib was defined as failure to achieve a complete hematologic response (CHR; after 3 months), major cytogenetic response (MCyR; after 6 months), or complete cytogenetic response (CCyR; after 12 months); or loss of a previous molecular response (with concurrent ≥ 10% increase in Ph+ metaphases), cytogenetic response, or hematologic response. Imatinib intolerance was defined as inability to tolerate 400 mg or more of imatinib per day or discontinuation of imatinib because of toxicity.
Results described below are based on a minimum of 2 years follow up after the start of SPRYCEL therapy in patients with a median time from initial diagnosis of approximately 5 years. Across all studies, 48% of patients were women, 81% were white, 15% were black or Asian, 25% were 65 years of age or older, and 5% were 75 years of age or older. Most patients had long disease histories with extensive prior treatment, including imatinib, cytotoxic chemotherapy, interferon, and stem cell transplant. Overall, 80% of patients had imatinibresistant disease and 20% of patients were intolerant to imatinib. The maximum imatinib dose had been 400–600 mg/day in about 60% of the patients and > 600 mg/day in 40% of the patients.
The primary efficacy endpoint in chronic phase CML was MCyR, defined as elimination (CCyR) or substantial diminution (by at least 65%, partial cytogenetic response) of Ph+ hematopoietic cells. The primary efficacy endpoint in accelerated phase, myeloid blast phase, lymphoid blast phase CML, and Ph+ ALL was major hematologic response (MaHR), defined as either a CHR or no evidence of leukemia (NEL).
Chronic Phase CML
Dose-Optimization Trial: A randomized, open-label trial was conducted in patients with chronic phase CML to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. Patients with significant cardiac diseases, including myocardial infraction within 6 months, congestive heart failure within 3 months, significant arrhythmias, or QTc prolongation were excluded from the trial. The primary efficacy endpoint was MCyR in patients with imatinib-resistant CML. A total of 670 patients, of whom 497 had imatinib-resistant disease, were randomized to the SPRYCEL 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily group. Median duration of treatment was 22 months.
Efficacy was achieved across all SPRYCEL treatment groups with the once daily schedule demonstrating comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint (difference in MCyR 1.9%; 95% CI [-6.8%–10.6%]); however, the 100-mg once-daily regimen demonstrated improved safety and tolerability.
Efficacy results are presented in Tables 10, 11, and 12 for patients with chronic phase CML who received the recommended starting dose of 100 mg once daily.
Table 10: Efficacy of SPRYCEL in Patients with
Imatinib Resistant or Intolerant Chronic Phase CML (minimum of 24 months
|All Patients||100 mg Once Daily (n=167)|
|Hematologic Response Rate % (95% CI)|
|Cytogenetic Response Rate % (95% CI)|
|a CHR (response confirmed after 4 weeks): WBC ≤
institutional ULN, platelets < 450,000/mm3, no blasts or
promyelocytes in peripheral blood, < 5% myelocytes plus metamyelocytes in
peripheral blood, basophils in peripheral blood < 20%, and no extramedullary
b MCyR combines both complete (0% Ph+ metaphases) and partial ( > 0%–35%) responses.
Table 11: Long-Term MMR of
SPRYCEL in the Dose Optimization Trial: Patients with Imatinib Resistant or
Intolerant Chronic Phase CMLa
|Minimum Follow-up Period|
|2 Years||5 Years||7 Years|
|Major Molecular Responseb % (n/N)|
|All Patients Randomized||34% (57/167)||43% (71/167)||44% (73/167)|
|Imatinib-Resistant Patients||33% (41/124)||40% (50/124)||41% (51/124)|
|Imatinib-Intolerant Patients||37% (16/43)||49% (21/43)||51% (22/43)|
|a Results reported in recommended starting dose of 100 mg
bMajor molecular response criteria: Defined as BCR-ABL/control transcripts ≤ 0.1% by RQ-PCR in peripheral blood samples.
Based on data 7 years after the last patient was enrolled in the trial, 44% were known to be alive, 31% were known to have died, and 25% had an unknown survival status.
By 7 years, transformation to either accelerated or blast phase occurred in nine patients on treatment in the 100 mg once daily treatment group.
Advanced Phase CML and Ph+ ALL
Dose-Optimization Trial: One randomized open-label trial was conducted in patients with advanced phase CML (accelerated phase CML, myeloid blast phase CML, or lymphoid blast phase CML) to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. The primary efficacy endpoint was MaHR. A total of 611 patients were randomized to either the SPRYCEL 140 mg once daily or 70 mg twice daily group. Median duration of treatment was approximately 6 months for both treatment groups. The once daily schedule demonstrated comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint; however, the 140-mg once daily regimen demonstrated improved safety and tolerability.
Response rates for patients in the 140 mg once daily group are presented in Table 12.
Table 12: Efficacy of
SPRYCEL in Imatinib Resistant or Intolerant Advanced Phase CML and Ph+ ALL (2
|140 mg Once Daily|
|MaHRa (95% CI)||66% (59-74)||28% (18-40)||42% (26-61)||38% (23-54)|
|CHRa (95% CI)||47% (40-56)||17% (10-28)||21% (9-39)||33% (19-49)|
|NELa (95% CI)||19% (13-26)||11% (5-20)||21% (9-39)||5% (1-17)|
|MCyRb (95% CI)||39% (31-47)||28% (18-40)||52% (34-69)||70% (54-83)|
|CCyR (95% CI)||32% (25-40)||17% (10-28)||39% (23-58)||50% (34-66)|
|a Hematologic response criteria (all responses confirmed
after 4 weeks): Major hematologic response: (MaHR) = complete hematologic
response (CHR) + no evidence of leukemia (NEL). CHR: WBC ≤ institutional
ULN, ANC ≥ 1000/mm3, platelets ≥ 100,000/mm3,
no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤ 5%,
< 5% myelocytes plus metamyelocytes in peripheral blood, basophils in
peripheral blood < 20%, and no extramedullary involvement. NEL: same criteria
as for CHR but ANC ≥ 500/mm3 and < 1000/mm3 , or
platelets ≥ 20,000/mm3 and ≤ 100,000/mm3 .
b MCyR combines both complete (0% Ph+ metaphases) and partial ( > 0%–35%) responses.
CI = confidence interval ULN = upper limit of normal range.
In the SPRYCEL 140 mg once daily group, the median time to MaHR was 1.9 months minmax:0.7-14.5) for patients with accelerated phase CML, 1.9 months (min-max:0.9-6.2) for patients with myeloid blast phase CML, and 1.8 months (min-max:0.9-2.8) for patients with lymphoid blast phase CML.
In patients with myeloid blast phase CML, the median duration of MaHR was 8.1 months (minmax:2.7-21.1) and 9.0 (min-max:1.8-23.1) months for the 140 mg once daily group and the 70 mg twice daily group, respectively. In patients with lymphoid blast phase CML, the median duration of MaHR was 4.7 months (min-max:3.0-9.0)and 7.9 months (min-max:1.6-22.1) for the 140 mg once daily group and the 70 mg twice daily group, respectively. In patients with Ph+ ALL who were treated with SPRYCEL 140 mg once daily, the median duration of MaHR was 4.6 months (min-max:1.4-10.2). The medians of progression-free survival for patients with Ph+ ALL treated with SPRYCEL 140 mg once daily and 70 mg twice daily were 4.0 months (min-max:0.4-11.1) and 3.1 months(min-max:0.3-20.8), respectively.
Last reviewed on RxList: 9/4/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Sprycel Information
Sprycel - User Reviews
Sprycel User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.